You Are Leaving Avistone's Website

You have selected a link that will take you to a site maintained by a third party. Avistone provides this link as a service to website visitors. Avistone is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit. Click 'Cancel' to return to Avistone's site or 'Continue' to proceed.

NEWS

NEWS

[2026 WCLC] e-Poster: Avistone Announces Results of a Phase II Study of Vebreltinib as Neoadjuvant Therapy in NSCLC with MET Alterations

Author:Avistone Time:2026-09-12

From September 12–15, 2026 (local time), the 27th World Conference on Lung Cancer (WCLC), hosted by the International Association for the Study of Lung Cancer (IASLC), was held at the COEX Convention Center in Seoul, South Korea. At this congress, Beijing Avistone Biotechnology Co., Ltd. (hereinafter referred to as Avistone) presented, for the first time, an e-Poster reporting the interim results of a Phase II study of Vebreltinib as neoadjuvant therapy in non-small cell lung cancer (NSCLC) with MET alterations.

01

PART ONE

Poster

Poster 3497

Poster Title: Vebreltinib with or without chemotherapy as neoadjuvant therapy in NSCLC with MET Alterations: A cohort, phase II study[1]

Principal Investigators: Yifei Zhou, Dongliang Bian, Peng Zhang (Department of Thoracic Surgery, Shanghai Pulmonary Hospital)

Conference Date: 23:55 KST / UTC+9, September 15, 2026

Registration: NCT06644313 | Data cutoff: August 10, 2026

Poster Link: https://cattendee.abstractsonline.com/meeting/21487/Session/173

Poster Abstract

MET-TKIs are currently the standard treatment for NSCLC with MET exon 14 skipping mutations or MET amplification. Although there are ongoing studies of neoadjuvant therapy for NSCLC with MET alterations, no data have yet been released. Vebreltinib has been conditionally approved for the treatment of locally advanced or metastatic NSCLC with MET exon 14 skipping mutations and MET amplification in China.[2][3] This study aims to evaluate the efficacy and safety of Vebreltinib as neoadjuvant therapy in NSCLC with MET alterations .

 

02

PART TWO

Background

At present, perioperative treatment for resectable MET-altered NSCLC still relies mainly on chemotherapy or chemo-immunotherapy, and there is a lack of precision neoadjuvant regimens targeting the MET-driven alterations. Although Vebreltinib has been conditionally approved for locally advanced or metastatic NSCLC with MET exon 14 skipping mutations and MET amplification, evidence of its value as neoadjuvant therapy in resectable patients remains limited. This study aims to explore the use of a highly selective c-MET inhibitor as neoadjuvant therapy in this population, to evaluate whether moving targeted therapy earlier can improve surgical resection rate and pathological response, and to provide a potential precision treatment option for the perioperative management of patients with this rare target.

 

03

PART THREE

Study Design 

Eligible patients were treatment-naïve patients with histologically or cytologically confirmed resectable NSCLC (stage IIIA–IIIB N2) and confirmed as c-MET alterations: MET exon 14 skipping mutation, MET amplification, or MET overexpression (IHC ≥50% 2+), with an ECOG PS of 0–2. The study used a single-arm cohort design, with a planned enrollment of 31 patients in Cohorts A+B and 40 patients in Cohort C.

  • Cohort A: MET exon 14 skipping mutation → Vebreltinib 200 mg BID for 4 months (neoadjuvant monotherapy);
  • Cohort B: MET amplification → Vebreltinib 200 mg BID for 4 months (neoadjuvant monotherapy);
  • Cohort C: MET overexpression → Vebreltinib 150 mg BID + chemotherapy once every 3 weeks for 4 cycles.

The primary endpoint was objective response rate (ORR; RECIST v1.1). Secondary endpoints included disease control rate (DCR), major pathological response (MPR), pathological complete response (pCR), event-free survival (EFS), overall survival (OS), and safety indicators. This poster presents only the interim data for Cohort A; results for Cohort B (MET amplification, monotherapy) and Cohort C (MET overexpression, combination therapy) have not yet been disclosed.

Baseline Characteristics of Cohort A

As of August 10, 2026, 20 patients have been enrolled in Cohort A, with a median follow-up of 9.5 months (0.8–21.6). The median age was 71 years (55–80); 11 patients were male and 14 (70%) had never smoked. Clinical stage was IIIA in 12 patients (60%) and IIIB in 8 (40%). Histologically, adenocarcinoma was predominant (11 patients, 55%), with adenosquamous carcinoma in 2 (10%), sarcomatoid carcinoma in 3 (15%), and other types in 4 (20%). ECOG PS was 0 in 13 patients (65%) and 1 in 7 (35%).

Table 1. The Characteristics of Cohort A (n=20)

Characteristic

n (%)

Median age, years (range)

71 (55–80)

Male / Female

11 (55) / 9 (45)

ECOG PS 0 / 1

13 (65) / 7 (35)

Never / Former / Current smoker

14 (70) / 5 (25) / 1 (5)

IIIA / IIIB

12 (60) / 8 (40)

Adenocarcinoma / Adenosquamous / Sarcomatoid / Other

11 (55) / 2 (10) / 3 (15) / 4 (20)

Efficacy

Among the 20 patients, 14 had completed neoadjuvant therapy. Per RECIST v1.1, the ORR was 85.7% (12/14) and the DCR was 100% (14/14). Ten patients underwent surgery with R0 resection achieved in 9 (90%). The pCR rate was 20% (2/10) and the MPR rate was 40% (4/10). Four patients did not undergo surgery: 3 declined surgery due to age ≥77 years, and 1 was ineligible for surgery. As of the data cutoff date, no recurrence  or death had be observed during follow-up.

Table 2. The Efficacy and Pathological Response in Cohort A

ORR, n (%)

DCR, n (%)

R0 Resection, n (%)

pCR, n (%)

MPR, n (%)

12 (85.7)

14 (100)

9 (90)

2 (20)

4 (40)

*1 patient without R0 resection: due to unclear demarcation between right hilar lymph nodes and adjacent tracheovascular structures,  with high bleeding risk, aggressive dissection was avoided. The denominators for R0, pCR, and MPR are the 10 patients who underwent surgery; the denominators for ORR and DCR are the 14 patients who completed neoadjuvant therapy and were evaluable. 

Surgical Outcomes

Among the 10 patients who underwent surgery, 7 (70%) had Video-Assisted Thoracoscopic Surgery (VATS), 2 (20%) had robot-assisted lung resection, and 1 (10%) had conversion from VATS to open thoracotomy. The median residual tumor volume was 20% (5–80), and the median operative time was 2.0 hours (1.5–5.83). Tissue adhesion was observed in 5 patients (50%), the median estimated blood loss was 20 mL (10–200), and no intraoperative blood transfusion was required. The median drainage tube removal time was 5 days (3–18), and median postoperative length of hospital stay was 5 days (3–12).

Table 3. Surgical Outcomes (n=10)

Item

Result

VATS / VATS conversion to open / Robot-assisted, n (%)

7 (70) / 1 (10) / 2 (20)

Residual tumor volume, % (range)

20 (5–80)

Operative time, hours (range)

2.0 (1.5–5.83)

Tissue adhesion, n (%)

5 (50)

Estimated blood loss, mL (range)

20 (10–200)

Intraoperative blood transfusion, n (%)

0 (0)

Drainage tube removal time, days (range)

5 (3–18)

Postoperative length of hospital stay, days (range)

5 (3–12)

Safety

The safety analysis set for Cohort A comprised 20 patients. Treatment-related adverse events (TRAEs) occurred in 85% (17/20) of patients, with Grade ≥3 TRAEs in 25% (5/20). One treatment-related serious adverse events (SAEs) was reported (5%). Dose reductions due to TRAEs occurred in 6 patients (30%), and no patient discontinued treatment due to TRAEs. The most common TRAEs(with an incidence of>20%) were peripheral edema (55%), AST increased (55%), ALT increased (50%), hypoalbuminemia (30%), rash (30%), and creatinine increased (20%). Grade ≥3 adverse events mainly occurred in increased AST and increased ALT (25% each); no Grade ≥3 peripheral edema was reported.

Table 4. Treatment-Related Adverse Events in Cohort A (n=20)

AE, n (%)

All Grades

Grade ≥3

TRAE

17 (85)

5 (25)

Treatment-related SAE

1 (5)

1 (5)

TRAE leading to dose reduction

6 (30)

5 (25)

TRAE leading to discontinuation

0

0

TRAEs occurring in >20% of patients

Peripheral edema

11 (55)

0

AST increased

11 (55)

5 (25)

ALT increased

10 (50)

5 (25)

Hypoalbuminemia

6 (30)

0

Rash

6 (30)

0

Creatinine increased

4 (20)

0

 

04

PART FOUR

Study Conclusion

These data indicate that Vebreltinib demonstrates clear clinical benefit in Cohort A, with a Grade ≥3 TRAE rate of 25%, supporting its potential as a neoadjuvant treatment option for NSCLC with MET exon 14 skipping mutations. A longer follow-up and a larger multi-center trial are warranted to further verify its clinical value.

References

[1] Zhou Y, Bian D, Zhang P. Vebreltinib with or without chemotherapy as neoadjuvant therapy in NSCLC with MET Alterations: A cohort, phase II study. WCLC 2026 Poster #3497. NCT06644313. Data cutoff: 2026-08-10.

[2] https://www.nmpa.gov.cn/zhuanti/cxylqx/cxypxx/20231116102348157.html

[3] https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20250630161536179.html

 

Forward-Looking Statements

The forward-looking statements made in this article relate only to events or information as of the date on which such statements are made in this article. Except as required by law, after the date of making the forward-looking statements, we shall have no obligation to update or publicly revise any forward-looking statements or unforeseen events, regardless of whether new information, future events or other circumstances arise. Please read this article carefully and understand that our actual future results or performance may differ materially from expectations. All statements contained in this article are made as of the publication date of this article and are subject to change in light of future developments.